Your browser doesn't support javascript.
loading
A new ER-specific photosensitizer unravels (1)O2-driven protein oxidation and inhibition of deubiquitinases as a generic mechanism for cancer PDT.
Pinto, A; Mace, Y; Drouet, F; Bony, E; Boidot, R; Draoui, N; Lobysheva, I; Corbet, C; Polet, F; Martherus, R; Deraedt, Q; Rodríguez, J; Lamy, C; Schicke, O; Delvaux, D; Louis, C; Kiss, R; Kriegsheim, A V; Dessy, C; Elias, B; Quetin-Leclercq, J; Riant, O; Feron, O.
Affiliation
  • Pinto A; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.
  • Mace Y; Institute of Condensed Matter and Nanosciences Molecules, Solids and Reactivity (IMCN/MOST), Université catholique de Louvain, Louvain-la-Neuve, Belgium.
  • Drouet F; Institute of Condensed Matter and Nanosciences Molecules, Solids and Reactivity (IMCN/MOST), Université catholique de Louvain, Louvain-la-Neuve, Belgium.
  • Bony E; Pharmacognosy Research Group (GNOS), Louvain Drug Research Institute (LDRI), Université Catholique de Louvain, Louvain-la-Neuve, Belgium.
  • Boidot R; Institute of Condensed Matter and Nanosciences Molecules, Solids and Reactivity (IMCN/MOST), Université catholique de Louvain, Louvain-la-Neuve, Belgium.
  • Draoui N; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.
  • Lobysheva I; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.
  • Corbet C; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.
  • Polet F; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.
  • Martherus R; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.
  • Deraedt Q; Institute of Condensed Matter and Nanosciences Molecules, Solids and Reactivity (IMCN/MOST), Université catholique de Louvain, Louvain-la-Neuve, Belgium.
  • Rodríguez J; Systems Biology Ireland, Conway Institute, Belfield, Dublin 4, Ireland.
  • Lamy C; Institute of Condensed Matter and Nanosciences Molecules, Solids and Reactivity (IMCN/MOST), Université catholique de Louvain, Louvain-la-Neuve, Belgium.
  • Schicke O; Institute of Condensed Matter and Nanosciences Molecules, Solids and Reactivity (IMCN/MOST), Université catholique de Louvain, Louvain-la-Neuve, Belgium.
  • Delvaux D; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.
  • Louis C; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.
  • Kiss R; Laboratoire de Cancérologie et de Toxicologie Expérimentale, Faculté de Pharmacie, Université Libre de Bruxelles, Brussels, Belgium.
  • Kriegsheim AV; Systems Biology Ireland, Conway Institute, Belfield, Dublin 4, Ireland.
  • Dessy C; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.
  • Elias B; Institute of Condensed Matter and Nanosciences Molecules, Solids and Reactivity (IMCN/MOST), Université catholique de Louvain, Louvain-la-Neuve, Belgium.
  • Quetin-Leclercq J; Pharmacognosy Research Group (GNOS), Louvain Drug Research Institute (LDRI), Université Catholique de Louvain, Louvain-la-Neuve, Belgium.
  • Riant O; Institute of Condensed Matter and Nanosciences Molecules, Solids and Reactivity (IMCN/MOST), Université catholique de Louvain, Louvain-la-Neuve, Belgium.
  • Feron O; Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium.
Oncogene ; 35(30): 3976-85, 2016 07 28.
Article in En | MEDLINE | ID: mdl-26686091
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxygen / Photochemotherapy / Photosensitizing Agents / Endoplasmic Reticulum / Deubiquitinating Enzymes / Neoplasms Limits: Animals / Humans Language: En Journal: Oncogene Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2016 Document type: Article Affiliation country: Bélgica Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Oxygen / Photochemotherapy / Photosensitizing Agents / Endoplasmic Reticulum / Deubiquitinating Enzymes / Neoplasms Limits: Animals / Humans Language: En Journal: Oncogene Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2016 Document type: Article Affiliation country: Bélgica Country of publication: Reino Unido